Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:36:01.325Z.
Calculation as of: 2026-10-06T16:36:01.325Z.
Quote observation: 2026-10-06T16:27:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e63cfa3374dfee63d003aa2d719039dd03588a75c4c3d0a37d7a31dccb95aa44
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$8.90B
PE Ratio
133.82
TTM Avg
133.81
3Y Avg
61.10
5Y Avg
61.10
Market Cap
$8.77B
PE Ratio
N/A
TTM Avg
41.90
3Y Avg
41.90
5Y Avg
41.90
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bruker Corporation (BRKRP) | $9.00B | N/A | N/A | N/A | N/A |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.98B | N/A | N/A | N/A | N/A |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.90B | 133.82 | 133.81 | 61.10 | 61.10 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.77B | N/A | 41.90 | 41.90 | 41.90 |
| Bruker Corporation (BRKR)vs › | $9.31B | N/A | 54.08 | 39.03 | 41.91 |
| Insulet Corp. (PODD)vs › | $9.40B | 25.35 | 58.80 | 65.23 | 3594.22 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.59B | N/A | N/A | N/A | N/A |
| Vaxcyte, Inc. (PCVX)vs › | $9.55B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.44B | 23.26 | 22.16 | 45.57 | 45.57 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.66B | 41.06 | 40.13 | 207.84 | 207.84 |
Trailing P/E
N/A
Forward P/E
211.5
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$448.82
Forward EPS (Est.)
$2.12
Forward P/E
211.50
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2025-11-05 | 618.50 |
| 2025-11-04 | 617.98 |
| 2025-11-03 | 594.46 |
| 2025-10-31 | 608.17 |
| 2025-10-30 | 593.37 |
| 2025-10-29 | 593.37 |
| 2025-10-28 | 593.37 |
| 2025-10-27 | 596.88 |
| 2025-10-24 | 614.62 |
| 2025-10-23 | 611.38 |
| 2025-10-22 | 611.38 |
| 2025-10-21 | 611.38 |
| 2025-10-20 | 599.88 |
| 2025-10-17 | 577.37 |
| 2025-10-16 | 575.77 |
| 2025-10-15 | 575.77 |
| 2025-10-14 | 555.77 |
| 2025-10-13 | 555.77 |
| 2025-10-10 | 555.77 |
| 2025-10-09 | 547.73 |
| 2025-10-08 | 547.73 |
| 2025-10-07 | 547.73 |
| 2025-10-06 | 572.87 |
| 2025-10-03 | 575.00 |
| 2025-10-02 | 551.33 |
| 2025-10-01 | 547.29 |
| 2025-09-30 | 522.69 |
| 2025-09-29 | 504.62 |
| 2025-09-26 | 504.88 |
| 2025-09-25 | 503.02 |
| 2025-09-24 | 514.40 |
| 2025-09-23 | 523.96 |
| 2025-09-22 | 523.96 |
| 2025-09-19 | 530.38 |
| 2025-09-18 | 530.38 |
| 2025-09-17 | 514.90 |
| 2025-09-16 | 526.92 |
| 2025-09-15 | 514.54 |
| 2025-09-12 | 514.54 |
| 2025-09-11 | 509.90 |
| 2025-09-10 | 503.83 |
| 2025-09-09 | 504.81 |
| 2025-09-08 | 494.71 |
| 2025-09-05 | 493.27 |
| 2025-09-04 | 481.73 |
